Clinical trials: Lines Skin
Triple-negative Breast Cancer
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
- Trial name
- NCT04750382
- Testing
- HX008+Cisplatin+Gemcitabine
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Periorbital Hyperpigmentation, Periorbital Edema
A 12 Week Study to Evaluate the Efficacy of an Eye Cream
This single center, open-label clinical study was conducted to assess the efficacy and tolerance of a topical eye cream when used over the course of 12 weeks by healthy women with moderate to severe under-eye dark circles…
- Conditions
- Periorbital Hyperpigmentation, Periorbital Edema, Fine Lines, Wrinkle
- Trial name
- NCT05807620
- Testing
- Gentle Cleansing Lotion, Facial Moisturizer, Sunscreen SPF 30
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Revision Skincare
Breast Cancer
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00033514
- Testing
- trastuzumab, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic breast cancer patients who recieved…
- Trial name
- NCT02030678
- Testing
- irinotecan
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Female Breast Carcinoma, Breast Cancer
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
This is an open-label, pilot study designed to evaluate the safety and feasibility of combining anastrozole and palbociclib in the following two cohorts: Cohort A) as first-line therapy and Cohort B) as maintenance therapy after…
- Trial name
- NCT02942355
- Testing
- anastrozole, Palbociclib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes
The purpose of this study is to determine whether cabazitaxel is effective in the treatment of metastatic breast cancer.
- Trial name
- NCT01693549
- Testing
- Cabazitaxel
- Where
- 17 sites in Greece
- Volunteers
- 84 people
- Sponsor
- Hellenic Cooperative Oncology Group
Metastatic Breast Cancer
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
To investigate the benefits and risks of maintenance chemotherapy (MCT), maintenance endocrine therapy (MET) and none maintenance therapy after first-line treatment of metastatic breast cancer (MBC).
- Trial name
- NCT04258163
- Testing
- Capecitabine, Liposomal doxorubicin, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 760 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast cancer over-expressing…
- Trial name
- NCT00372424
- Testing
- Herceptin, Sunitinib, Taxotere
- Where
- 7 sites in Belgium, Italy
- Volunteers
- 26 people
- Sponsor
- Pfizer
Breast Tumor, Breast Cancer
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects…
- Conditions
- Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer
- Trial name
- tnAcity (NCT01881230)
- Testing
- nab-Paclitaxel, Carboplatin, Gemcitabine
- Where
- 140 sites in United States, Australia and 10 more
- Volunteers
- 191 people
- Sponsor
- Celgene
Primary Immunodeficiency, DOCK8
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Background: National Institutes of Health (NIH) researchers have been studying immune cells (white blood cells) to better understand how the human body s defense system works and adjusts or regulates itself, and how changes in…
- Conditions
- Primary Immunodeficiency, DOCK8, Virus Susceptibility
- Trial name
- NCT00895271
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Thrombocytopenia
The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia
A randomized, open-label, multicenter study to compare the efficacy and safety of terbutaline plus danazol compared to danazol monotherapy for the second-line treatment of adults with corticosteroid-resistant or relapsed primary…
- Trial name
- NCT05494307
- Testing
- Terbutaline, Danazol
- Volunteers
- 228 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia
Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of zanubrutinib plus eltrombopag compared to eltrombopag monotherapy for the first-line treatment of adults with chronic immune thrombocytopenia (ITP).
- Trial name
- NCT05369377
- Testing
- Zanubrutinib, Eltrombopag
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University People's Hospital
Breast Neoplasms
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
The purpose of this study is to learn how breast cancer tumors respond to treatment combining the drugs docetaxel and ZD1839.
- Trial name
- NCT00052169
- Testing
- ZD1839 in combination with docetaxel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- NSABP Foundation Inc
Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin Diseases. After collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a…
- Conditions
- Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum, Erosive Pustular Dermatosis of the Scalp, Sweet's Syndrome
- Trial name
- NEUTROGENE (NCT01952275)
- Testing
- Collection of biological samples
- Where
- Switzerland
- Volunteers
- 600 people
- Sponsor
- University of Zurich
Locally Advanced or Metastatic Breast Cancer
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally…
- Trial name
- NCT07461454
- Testing
- YL202, Eribulin, Capecitabine
- Where
- China
- Volunteers
- 376 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Triple Negative Breast Neoplasms
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
- Trial name
- CAPItello-290 (NCT03997123)
- Testing
- Capivasertib, Paclitaxel
- Where
- 260 sites in United States, Argentina and 28 more
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
Breast Cancer
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition…
- Trial name
- NCT00448279
- Testing
- trastuzumab, Chemotherapy
- Where
- 35 sites in Italy
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
Evaluate the safety and efficacy of Pyrotinib at different doses in combination with trastuzumab and paclitaxel chemotherapy for first-line treatment of HER2-positive advanced breast cancer.
- Trial name
- NCT06770296
- Testing
- Pyrotinib low dose group, Pyrotinib normal dose group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Metastastic Malignant Melanoma, Refractory to First-Line Chemotherapy Irresectable Progressive Soft Tissue Metastases
Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases
The incidence of malignant melanoma continues to rise throughout the world. Approximately 12 in 100,000 Germans are diagnosed with malignant melanoma per year.
- Trial name
- NCT00264056
- Testing
- hyperthermia
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Fachklinik Hornheide an der Universität Münster
Breast Cancer
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
This study aims to assess the activity of PD0332991 in monotherapy and in combination with the endocrine therapy (anastrozole, letrozole, exemestane or fulvestrant) on which the patient has progressed in the previous line for…
- Trial name
- TREnd (NCT02549430)
- Testing
- Palbociclib, Anastrozole, Letrozole
- Where
- 6 sites in Italy
- Volunteers
- 115 people
- Sponsor
- Fondazione Sandro Pitigliani